pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,838 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech779BioSpace767BioPharma Dive555raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3399Immunology3069Cardiology2870Hematology2337Pulmonology2300Vaccines
  • Kennedy and MAHA urged to champion MMR vaccine to curb U.S. measles surge
    After the United States lost its measles elimination status, health secretary Robert F. Kennedy Jr. used his X account to pledge action, stating the MMR vaccine remains the most effective tool to s…
    STAT · 4h agoPositive↗ source
  • Debate Over Whether Medical School Should Begin After USMLE Step 1 Exam
    STAT published an opinion essay proposing that medical school start after students take the Step 1 exam. The piece prompted letters to the editor, with readers offering personal reflections on the…
    STAT · 2h agoNeutral↗ source
← prev
page 1 of 154
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • FDA rejects Capricor’s Duchenne cell therapy after trials show no benefit
    The Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
    STAT · 14h agoRegulatoryNegative↗ source
  • Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapy
    Compass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
    BioPharma Dive · 18h agoRegulatoryNeutral↗ source
  • Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trial
    Erasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
    BioPharma Dive · 20h agoPositive readoutNeutral↗ source
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 1d agoDealNeutral↗ source
  • Greenwich Rx voluntarily recalls compounded sterile products over sterility concerns
    Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, announced a voluntary nationwide recall of certain compounded sterile product lots that are still within their beyond-use dates.…
    fda recalls · 14h agoCRLNegative↗ source
  • Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug prices
    Sanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…
    STAT · 23h agoDealNeutral↗ source
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 1d agoNegative readoutNegative↗ source
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 1d agoRegulatoryNeutral↗ source
  • FDA delays decision on Belite Bio's Stargardt disease drug to May 12
    The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
    Fierce Biotech · 1d agoRegulatoryNeutral↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • ICH Q1 Stability Testing Guideline Revision Expected Within Weeks
    The International Council for Harmonization announced that the revised ICH Q1 stability testing guideline has been adopted and will be published soon. The new version will be issued as a Step 4 gu…
    raps · 1d agoRegulatoryNeutral↗ source
  • Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasis
    Stakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…
    raps · 1d agoRegulatoryNeutral↗ source
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 1d agoRegulatoryNegative↗ source
  • Alterome reports early Phase 1 data for KRAS-targeted therapy in pancreatic, lung and colon cancers
    Alterome has unveiled preliminary Phase 1 data for its experimental KRAS-targeted therapy. The drug is designed to hit a spectrum of KRAS mutations that drive several solid tumours. The early stud…
    STAT · 1d agoPositive readoutNeutral↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 1d agoRegulatoryNegative↗ source
  • FDA outlines inspection focus on risk management for combination product manufacturers
    FDA officials said that manufacturers using a streamlined CGMP approach for combination products should expect the agency to closely scrutinize their risk management activities. The remarks were d…
    raps · 1d agoRegulatoryNeutral↗ source
  • Medicare launches pilot to test nutrition and exercise programs as preventive care for chronic disease
    Department of Health and Human Services announced that fifteen groups across the United States will participate in a Medicare pilot aimed at evaluating lifestyle interventions for chronic disease p…
    STAT · 18h agoRegulatoryPositive↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 1d agoNeutral↗ source
  • FDA faces push for flexible rare-disease trial designs as commissioner's nomination withdrawn
    The FDA’s weekly briefing highlighted several notable developments, including the sudden withdrawal of the Trump administration’s nominee for FDA commissioner at the last minute. The agency also a…
    raps · 1d agoRegulatoryNeutral↗ source
  • Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officer
    Ailux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…
    STAT · 22h agoNeutral↗ source
  • Exercise should be prescribed alongside rest for concussion recovery, author argues
    The author recounts a severe brain injury that left him in a coma, caused significant muscle loss and left-side weakness, and made simple tasks like getting out of a bathtub a struggle. He began a…
    STAT · 1d agoPositive↗ source
  • Patient coalition urges more agency for participants in brain-implant trials
    A new report released by the BCI Pioneers Coalition outlines 13 recommendations aimed at improving how brain‑computer interface trials are conducted. The guidance targets startups, researchers and…
    STAT · 1d agoNeutral↗ source